Assessment of patients with psoriasis undergoing treatment with narrowband UVB phototherapy in the State University of Pará, Brazil
Introduction: Moderate and severe forms of psoriasis require phototherapy and/or systemic medications. The UVB band, with wavelength between 311 and 312nm, is called narrowband UVB (NB-UVB) and it has proven to be more beneficial for the psoriasis treatment.
Goals: to characterize the group of patients with psoriasis treated with NB-UVB phototherapy, according to the clinical form, sex, phototype, and clinical evolution.
Methods: All patients with psoriasis who underwent NB-UVB phototherapy between August 2016 and April 2017 were included in this study. Data on the patients were collected retrospectively.
Results: During the study, 19 patients were treated with NB-UVB phototherapy, being 09 women (47%) and 10 men (53%), ages ranging from 22 to 81years. The most prevalent phototypes were III (42%) and IV (37%). Only 04 patients (21%) had guttate psoriasis and 15 (79%) had psoriasis vulgaris with variable severity. The total number of phototherapy sections, during the period evaluated, varied from 7 to 51, with an average of 25 sessions. It was observed that, 09 patients (47%) had a response beginning with up to two months of treatment. The minimum number of sections to start improvement varied from 8 to 28, with an average of 16 sessions.
Conclusions: The use of NB-UVB phototherapy proved to be a safe and effective treatment, and should be considered a good therapeutic option for psoriasis.
2. Lebwoh M. Psoriasis. Lancet. 2003; 361 (9364): 1197-204.
3. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005; 152:597-615.
4. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB Jr, Feldman SR. Psoriasis treatment in the United States at the end of 20th century. Int J Dermatol. 2006; 45:370-374.
5. Matz H. Phototherapy for psoriasis: what to choose and how to use: facts and controversies. Clinics in dermatology. 2010; 28(1):73-80.
6. Ledo E, Ledo A. Phototherapy, photochemotherapy, and photodynamic therapy: unapproved uses or indications. ClinDermatol. 2000; 18:77-86.
7. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001; 26: 343-350.
8. Barbagallo J, Spann CT, Tutrone WD, Weinberg JM. Narrowband UVB phototherapy for the treatment of psoriasis: a review and update. Cutis. 2001; 68:345-347.
9. Duarte I, Cunha JAJ, Bedrikow RB, Lazzarini R. What is the most common phototherapy prescription for psoriasis: NB-UVB or PUVA? Prescription behavior.. An Bras Dermatol. 2009; 84(3):244-48.
10. Cestari TF, Pessato S, Corrêa GP. Fototerapia – aplicações clínicas. An Bras Dermatol. 2007; 82(1):7-21
11. Diffey BL, Farr PM. The challenge of follow-up in narrowband ultraviolet B phototherapy. Br J Dermatol. 2007; 157: 344-349.
12. Duarte I, Buense R, Kobata C. Fototerapia. An Bras Dermatol. 2006; 81(1):74-82.
13. Paul C, Gallini A, Archier E, Castela E, Devaux S, Aractingi S, et al. Evidence-based recommendations on topical treatment and phototherapy of psoriasis: systematic review and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology : JEADV. 2012; 26 Suppl 3:1-10.
14. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, et al. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of dermatological research. 2012; 304(2):87-113.
15. Richard EG, Honigsmann H. Phototherapy, psoriasis, and the age of biologics. Photodermatology, photoimmunology & photomedicine. 2014;30(1):3-7.
16. Jensen P, Skov L, Zachariae C. Systemic combination treatment for psoriasis: a review. Acta dermato-venereologica. 2010; 90(4):341-9.
17. Coimbra S, Oliveira H, Belo L. Principal determinants of the length of remission of psoriasis vulgaris after topical, NB-UVB, and PUV A therapy: a follow-up study. Am J Clin Dermatol 2013;14:49–53.
18. Romaní J, Julià M, Lozano F. Toll-like receptor 9 promoter polymorphism as a predictive factor of narrow-band UVB phototherapy response in patients with psoriasis. Photodermatol Photoimmunol Photomed 2015; 31:98–103.
19. Rui W, Xiangyu D, Fang X, Long G, et al. Metabolic syndrome affects narrowband UVB phototherapy response in patients with psoriasis. Medicine (Baltimore) 2017; 96 (50).
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License ©